![logo](/logos/NKTR.webp)
Nektar Therapeutics
NASDAQ:NKTR
1.12 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Nektar Therapeutics |
Symbool | NKTR |
Munteenheid | USD |
Prijs | 1.12 |
Beurswaarde | 206,168,480 |
Dividendpercentage | 0% |
52-weken bereik | 0.41 - 1.93 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Howard W. Robin |
Website | https://www.nektar.com |
An error occurred while fetching data.
Over Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)